PRECLINICAL MEDICATIONS SCREENING FOR GENETIC MODELS OF ALCOHOLISM

这份合同是为了满足NIAAA神经科学和行为部临床前药物疗效测试计划的药物开发计划目前和预期的未来需求。这项替代合同将继续对P大鼠和HAD1大鼠的参考化合物和专有化合物进行盲法测试，这些化合物是为酒精偏好而选择性培育的。合同将使用具有有利于复合提供商的知识产权条件的机制。这将消除测试具有临床前和临床毒理学数据的优化化合物的主要障碍，并将激发制药业开发高质量、可销售的酒精中毒化合物的兴趣。工作说明要求被认为是可分离的。

This contract is to address the present and anticipated future needs of NIAAA’s Medication Development Program of the Division of Neuroscience and Behavior’s Preclinical Medication Efficacy Testing Program. This replacement contract will continue the blind testing of reference compounds and proprietary compounds in P rats and HAD1 rats selectively bred for alcohol preference. The contract will use mechanisms having intellectual property conditions favorable to compound providers. This will eliminate a major barrier to testing optimized compounds having preclinical as well as clinical toxicology data and will stimulate interest by the pharmaceutical industry in developing high quality, marketable compounds for alcoholism. The statement of work requirements are considered to be severable.